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Objectives
To investigate clinical and economic feasibility of using
genomic data in the context of antithrombotic drug therapy by
linking data from Finnish biobanks and national registries.
The specific objectives are:
1. To investigate clinical response to warfarin therapy in
individuals with and without specific genetic variants
2. To assess the clinical and economic impact of using
genotype data in guiding warfaring therapy
3. To employ data-driven classification methods to explore
genotype-phenotype associations for antithrombotic
drugs, including direct oral anticoagulants, clopidogrel
and heparins
Data sources
The following data and data sources are intended to be used: 
• Genotype data (Helsinki Biobank, THL Biobank, Auria 
Biobank)
• Laboratory data (laboratory registers)
• Healthcare encounters (National Institute for Health and 
Welfare)
• Drug purchases (Social Insurance Institution)
• Electronic health records
Participants
Inclusion criteria:
• ≥ 18 years of age
• Genotyped for variants in CYP2C9 and VKORC1
• Diagnosed with a disease of cardiovascular system.
• Purchased at least one of the following antithrombotic drugs
between 1.1.2007 - 31.12.2018:
• Warfarin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban, 
Heparin, Enoxaparin, Dalteparin, Clopidogrel, Ticagrelor, 
Acetylsalicylic acid
Sample size: 2678 patients are required to detect a risk ratio
(RR) of 1.8 for bleeding complications in carriers of variant
alleles CYP2C9*2 and CYP2C9*3 (α=0.05, power=0.9).
Outcomes measures
• Bleeding complications in warfarin users
• Time in Therapeutic Range (TTR) in warfarin users
• Drug dosage in warfarin users
• Healthcare encounters in warfarin users
• Clinical response to other antithrombotic drugs





VTT – beyond the obvious
www.vttresearch.com
Pharmacogenomics of antithrombotic drugs – a novel study design and data 
collection approach using Finnish biobanks and national registries
Anna-Leena Vuorinen1, Jaakko Lähteenmäki1, Mika Lehto2, Kari Harno3, Maija Wolf4, Mikko Niemi5
1 VTT Technical Research Centre of Finland Ltd, 2 Hospital District of Helsinki and Uusimaa, 
3 University of Eastern Finland, 4 Medaffcon Oy, 5 University of Helsinki
Background
Adverse drug reactions cause hospitalizations and even
premature deaths. Pharmacogenetic studies have identified a
number of gene variants that cause adverse drug responses
in individuals using antithrombotic drugs. Certain gene
variants affect drug metabolism increasing the risk for
bleeding.
Figure 1. Prevalence of CYP2C9 variant alleles and their
association with warfarin therapy.
Figure 2. Data sources.
Status and next steps
• Preparatory phase on-going (data permit applications 
and contracts)
• Data analysis planned to begin in September 2019 
(FinnGen genome data to be released for biobank 
studies)
• The study is carried out in the framework of the 
PreMed project
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